We sought to determine whether the clinical benefit of aspiration thrombectomy relative to IV r-tPA (recombinant tissuetype plasminogen activator) may be greater at longer TL. Methods-THERAPY was a randomized trial of aspiration thrombectomy plus IV r-tPA versus IV r-tPA alone in largevessel stroke patients with prospective TL measurement ≥8 mm. In this post hoc study, we evaluated the association of TL with trial end points and potential endovascular treatment effect, using univariate, multivariable, and multiplicative interaction analyses. Results-TL data were available for all 108 patients (28% internal carotid artery, 62% M1, and 10% M2). Median TL was 14.0 mm (interquartile range, 9.7-19.5 mm). Longer TL was associated with worse outcome (90-day modified Rankin Scale score: odds ratio, 1.24 per 5-mm TL increment; 95% confidence interval, 1.04-1.52; P=0.02), even after adjusting for key outcome predictors (adjusted P=0.004). Longer TL was also associated with more serious adverse events (adjusted P=0.01), more symptomatic hemorrhages (adjusted P=0.03), and increased mortality (adjusted P=0.01). No significant relationship was observed between TL and angiographic reperfusion (modified thrombolysis in cerebral ischemia 2b-3), but greater TL was associated with longer endovascular procedural times (ρ=0.36; P=0.045). Increasing TL was associated with greater aspiration thrombectomy treatment effect (interaction term P=0.03). This might be related to a potentially stronger adverse effect of increasing TL on 90-day modified Rankin Scale for patients treated with IV r-tPA (ρ=0.39; P=0.01) compared with intra-arterial therapy (ρ=0.20; P=0.165). Conclusions-Ischemic stroke patients with longer symptomatic thrombi have worse 90-day clinical outcomes but may have a greater relative benefit of aspiration thrombectomy over IV r-tPA alone. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01429350.
R ecent single-arm studies have examined various thrombus-imaging characteristics primarily using noncontrast computed tomography (NCCT) and have shown a significant impact on outcomes after both intravenous and intraarterial therapies. [1] [2] [3] [4] However, whether any of these thrombus attributes modifies endovascular treatment effect remains unknown. THERAPY was a prospective randomized controlled trial of bridging intra-arterial thrombectomy (IAT) using aspiration thrombectomy after intravenous (IV) r-tPA (recombinant tissue-type plasminogen activator) versus IV r-tPA alone. The trial was terminated prematurely given the new standard of care of endovascular therapy after announcement of the positive results from multiple IAT trials. [5] [6] [7] [8] [9] THERAPY mandated the prospective collection of thinsection NCCT data to assess thrombus length (TL) for consideration of trial eligibility; ischemic stroke patients were eligible for THERAPY if the symptomatic TL was ≥8 mm. Therefore, despite its relatively small sample size, THERAPY is uniquely positioned to assess the prognostic relevance of TL on treatment outcomes and, perhaps more importantly, to test whether it influences the treatment effect of IAT compared with IV r-tPA alone. We hypothesize that
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Methods
THERAPY was an international, multicenter, prospective, randomized, open-label, blinded end point trial of combined IV and IAT versus IV r-tPA alone in acute ischemic stroke patients with proximal arterial occlusion of the intracranial anterior circulation (internal carotid artery [ICA] and middle cerebral artery [MCA] M1 and proximal M2 segments). The full primary study design and results were previously reported. 10 Imaging eligibility criteria included the presence of proximal intracranial occlusion on baseline computed tomographic angiography, TL ≥8 mm on thin-section NCCT, the absence of tandem extracranial stenosis or occlusion that would require treatment before thrombectomy, and the absence of acute ischemic changes involving greater than one third of the affected MCA territory. Enrolling site technicians reconstructed thin-section images to ≤2.5-mm slice thickness at the computed tomographic scanner console, and clinical investigators prospectively determined TL before randomization. We had predefined thrombus as a tubular shaped structure within the ICA or MCA with X-ray attenuation higher than the remaining artery on NCCT. The research was conducted according to the principles of the Declaration of Helsinki.
Imaging Analysis
Baseline NCCT and computed tomographic angiography scans were deidentified and reviewed by the central imaging reader (A.J.Y.) to confirm fulfillment of all imaging enrollment criteria. The central reader was blinded to treatment allocation, and all clinical information except side of stroke involvement. To determine TL, thin-section NCCT data were reformatted to thick maximum-intensity projection images of 5-mm thickness with 1-to 2-mm overlap, in both the coronal and axial planes. Thrombus visualization was performed using window level/width setting of 50/50 Hounsfield units, although these were adjusted when necessary to optimize thrombus discrimination. TL was measured on both the coronal and axial maximum-intensity projection images, and the longest value was recorded, given likely foreshortening in one direction. For thrombi extending into the M2 segments, measurements were continued into the M2 branch containing the longest thrombus. Core lab-determined TL was used for all statistical analyses.
Statistical Analysis
Baseline clinical and imaging data were summarized using standard descriptive statistics. The association between TL and baseline characteristics was evaluated for significance using nonparametric tests. The association between TL and clinical and safety outcomes was tested using nonparametric univariate analyses, in addition to logistic regression adjusted for age, baseline National Institutes of Health Stroke Scale score, history of diabetes mellitus, and treatment allocation. Occlusion level (ICA versus MCA) was not adjusted for because of its collinearity with TL. All prespecified primary and secondary trial end points were examined, in addition to day 90 modified Rankin Scale (mRS) 0 to 3 and day 90 National Institutes of Health Stroke Scale score 0 to 2. Ordinal logistic regression was used to test the interaction between TL and treatment allocation for day 90 mRS distribution, after ensuring that the assumption of proportionality was satisfied. A sensitivity analysis was performed by removing the 7 patients who had TLs <8 mm according to the core laboratory reading. Statistical significance was set at a 2-sided P value <0.05. All statistical analyses were performed using SAS v9.4 (SAS Institute, Cary, NC).
Results

Baseline Data and Associations With TL
The trial was halted prematurely on October 29, 2014. 10 The final THERAPY cohort consisted of 108 patients (55 IAT arm; 53 IV r-tPA alone). The mean age was 69±11 years. There were 51 females (47%). The median National Institutes of Health Stroke Scale score was 18 (interquartile range, 14-22). Occlusion locations were 30 (28%) ICA, 67 (62%) MCA M1, and 11 (10%) MCA M2.
TL data were available for all 108 patients. Median TL was 14.0 mm (interquartile range, 9.7-19.5). In 101 subjects, the core laboratory TL reading was ≥8 mm. In 7 subjects, the TL measurements were 7.7, 7, 7, 6.2, 5.6, and 4.9, and in 1 patient, no hyperdense thrombus was visualized by the core laboratory. ICA occlusion, lower ASPECTS (Alberta Stroke Program Early CT Score), worse computed tomographic angiography collaterals, male sex, and higher blood glucose level were associated with greater TL (Table 1) .
Outcomes Versus TL
In the entire THERAPY cohort, longer TL was associated with higher 90-day mRS (odds ratio [OR], 1.24 per 5-mm TL increment; 95% confidence interval [CI], 1.04-1.52; P=0.02); other clinical end points were consistent with this finding as shown in Table 2 . For IAT versus IV r-tPA alone, respectively, 90-day mRS 0 to 2 rates were 41.2% (7/17) versus 35.3% (6/17) for the lowest tertile (TL ≤11.1 mm), 50% (8/16) versus 42.9% (6/14) for the middle tertile (TL 11.3-17.7 mm), and 23.5% (4/17) versus 13.3% (2/15) for the highest tertile (TL ≥18.0 mm).
Longer TL was also associated with lower final ASPECTS (OR, 0.73 per -mm TL increment; 95% CI, 0.60-0.86; P=0.0005). Longer TL also had higher rates of serious adverse events (OR, 1.28 per 5-mm TL increment; 95% CI, 1.04-1.64; P=0.03), higher rates of symptomatic intracranial hemorrhage (OR, 1.28 per 5-mm TL increment; 95% CI, 0.995-1.65; P=0.04), and increased mortality (OR, 1.26 per 5-mm TL increment; 95% CI, 1.01-1.58; P=0.04).
Among the IAT subjects, no significant relationship was found between TL and successful angiographic (modified thrombolysis in cerebral ischemia [mTICI] 2b-3) reperfusion; mTICI 2b-3 rates were 60% (9/15) in the lowest TL tertile, 84.6% (11/13) in the middle tertile, and 76.5% (13/17) in the highest tertile. However, greater TL was associated with longer procedural time to endovascular reperfusion (ρ=0.36; P=0.045). No revascularization data were available for the IV arm.
With increasing TL, there was a greater relative benefit of IAT over IV r-tPA alone (interaction term P=0.03; Figure) ; this relationship remained significant in adjusted analysis (interaction term P=0.049). This might be related to a potentially stronger adverse effect of increasing TL on 90-day mRS for IV r-tPA (ρ=0.39; P=0.01) compared with IAT (ρ=0.20; P=0.17), although the difference between the treatment arms did not reach statistical significance (P=0.32).
The findings with respect to the association of TL with baseline variables and clinical and imaging end points remained similar when the analysis was restricted to the 101 subjects who had TLs ≥8 mm according to the core laboratory.
There was substantial correlation between TLs determined by the site investigator and the core imaging laboratory (concordance correlation coefficient, 0.705; 95% CI, 0.696-0.714).
Discussion
In this post hoc analysis of the THERAPY trial, greater TL was independently associated with worse clinical and safety outcomes. This relationship was consistent across all trial end points. In adjusted analysis of 90-day ordinal mRS, there was a 33% relative increase in the likelihood of a worse outcome with every 5-mm increase in TL. In spite of the worse outcomes with longer TL, the relative benefit of IAT compared with IV r-tPA seemed to increase with longer TLs.
The detrimental effect of TL on clinical outcome is most likely attributable to the occlusion of side branches and the greater difficulty of recanalizing larger thrombi. Although recanalization data were not obtained in the IV arm of THERAPY, this relationship has been well documented in angiographic studies of IV r-tPA.
1,2 Regarding intra-arterial aspiration thrombectomy, the proportion of patients with substantial reperfusion (mTICI 2b-3) did not vary significantly in relation to TL, but the time to mTICI 2b-3 reperfusion was significantly longer with greater TL, although this correlation was weak. The differential impact of TL on outcomes in the 2 treatment arms (ie, greater detrimental effect in IV r-tPA patients) accounts for the paradoxical finding of increasing relative benefit of IAT despite the overall worse outcomes seen with longer thrombi. This finding illustrates the difference between prognostic and therapeutic biomarkers-increasing TL is simultaneously a negative prognostic biomarker and a positive therapeutic biomarker (ie, TL modifies treatment effect).
THERAPY was designed to identify a population with a lower chance of recanalization with IV r-tPA, specifically those with TL ≥8 mm. 1 However, more recent data suggest that some of these patients may still derive some benefit from intravenous thrombolysis. In one study of MCA M1 occlusions, IV r-tPA resolved the thrombus in 37.5% of cases with baseline TL of 10 to 20 mm, whereas no thrombi >20 mm recanalized. 2 Data from THERAPY seem to support these recent findings. Although there were few long thrombi in this trial, all patients in the IV arm with TL >25 mm (n=5) had 90-day mRS score >2. In the IAT arm, all patients with TL >35 mm (n=3) had 90-day mRS score >2, and that again supports the greater efficacy of IAT in recanalizing longer thrombotic occlusions.
ICA compared with MCA occlusion was associated with longer thrombi. It is unclear whether this is because greater thrombus burdens lodge in larger, more proximal arteries, or whether the weaker pial collaterals seen in ICA strokes promote stasis and thrombus propagation at the distal thrombus face. 11 Indeed, there was a significant inverse correlation between collateral strength and TL in this study. In addition, longer thrombi were associated with lower baseline ASPECTS, which may be explained by the greater chance for longer thrombi to occlude the origins of the lenticulostriate and insular perforators, for which collateral support is limited. Taken together, the dismal outcomes seen with ICA occlusions are likely because of a synergistic effect of worse collaterals, larger baseline infarct size, and longer thrombotic occlusions that are difficult to rapidly recanalize.
Our post hoc findings should be validated in other data sets. Additionally, they should be tested in relation to other †CTA collateral grading: 0=absent collaterals in half or greater of MCA territory; 1=absent collaterals in half of M2 territory or greater (>grade 0); 2=decreased (vs unaffected hemisphere) collaterals in half or greater of M2 territory; 3=decreased collateral in less than half of M2 territory; 4=equal or greater collaterals.
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intra-arterial treatment approaches, including stent retriever and combined stent retriever with local aspiration techniques. One study of mostly stent retriever thrombectomy demonstrated no significant relationship between TL on magnetic resonance imaging (MRI) susceptibility-weighted imaging and successful reperfusion (mTICI 2b-3), similar ASPECTS indicates Alberta Stroke Program Early CT Score; CI, confidence interval; mRS, modified Rankin Scale; mTICI, modified thrombolysis in cerebral ischemia; NIHSS, National Institutes of Health Stroke Scale; NCCT, noncontrast computed tomography; SAE, serious adverse events; and sICH, symptomatic intracerebral hemorrhage.
*Adjusted for age, baseline NIHSS score, history of diabetes mellitus, and treatment allocation. †mRS 0-2 at 30 d, ≥10 point NIHSS score improvement from baseline to 24 h, or NIHSS 0-1 at discharge. ‡Final ASPECTS determined on 24-h NCCT.
Figure.
The common odds ratio indicating the relative benefit of combined intravenous and intra-arterial therapy vs intravenous tPA (tissue-type plasminogen activator) alone, as a function of thrombus length. IAT indicates intra-arterial thrombectomy.
to our analysis. 12 However, no data on time to reperfusion was provided. A critical area of research will be to identify which methods are best able to address stroke with greater thrombus burdens. Additionally, further work should explore the effects of other thrombus attributes such as thrombus density and contrast permeability on treatment outcomes. 4, [13] [14] [15] Advances in biomechanical characterization of thrombi will aid in optimizing endovascular devices and techniques. Until more data are available, TL measurement should not be used for treatment decision making. Prognostication and endovascular triage based on TL before thrombectomy should also be approached with caution. Although the relationship between TL and IV r-tPA efficacy is better established, its impact on triage to IAT may be minimal given recent broadly positive trial results. 16 The primary limitation of this analysis is that short thrombi were under-represented, because of the trial design. Therefore, extrapolation of the current results to short thrombi is questionable. Specifically, one should be wary of the finding that the point estimate for the common odds ratio favors IV r-tPA at TLs <8 mm ( Figure) . Those with shorter TLs still may have better outcomes with IAT compared with IV r-tPA. Patients with ICA terminus or M1 occlusions should be treated with intra-arterial therapy regardless of TL, provided they are otherwise good treatment candidates. 17 An additional limitation is related to the use of NCCT for thrombus detection and measurement. Although thin-section NCCT has been demonstrated to provide accurate TL measurement, 18 it is less sensitive than blooming artifact on MRI gradient echo imaging or susceptibility-weighted imaging. Consequently, we did not detect cases with multiple thrombus fragments, whereas one series using susceptibility-weighted imaging reported a 7.4% rate among 324 patients. 19 However, it is also unclear to what extent the increased sensitivity of MRI affects TL measurement, as the degree of blooming artifact is dependent on factors such as thrombus composition, field strength, and sequence parameters. Unfortunately, there are no comparative studies of TL imaged with both thin-section NCCT and MRI susceptibility-weighted imaging. In addition, with NCCT, it may be difficult to detect the proximal end of thrombi that involve the petrocavernous segments because of streak artifact at the skull base. However, a similar issue may be encountered with MRI, where susceptibility effects at the skull base will limit thrombus evaluation in this region.
Conclusions
In acute ischemic stroke patients with anterior circulation large vessel occlusion, increasing TL is associated with worse clinical and safety outcomes after intravenous and intraarterial reperfusion therapies. The superiority of IAT over IV r-tPA increases with TL.
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